Since multiple reports suggested that TREX1 has a protumorigenic effect and contributes to cancer resistance to therapy [13, 15, 29, 43–45, 47–52], the presence of TREX1 variants in tumor samples may have important clinical implications. Here, TREX1 is linked to neoplasm.